Advanced glycation end products in uremia

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • TUD Dresden University of Technology
  • Tokai University

Abstract

The term "advanced glycation end products" (AGEs) stands for a heterogenous group of amino acid derivatives that are formed via glycation processes between peptide-bound lysine or arginine derivatives and carbonyl compounds, processes originally known from food systems as "Maillard reactions." AGEs accumulate in plasma and tissues with advancing age, diabetes, and particular renal failure. In vivo and in vitro studies indicate that AGEs represent an important class of uremic toxins. This review focuses on the chemistry behind the formation of AGEs, possible mechanisms underlying the accumulation of AGEs in uremia, clinical and therapeutic implications, and possible nutritional consequences. (C) 2003 by the National Kidney Foundation, Inc.

Details

Original languageEnglish
Pages (from-to)321-331
Number of pages11
JournalAdvances in renal replacement therapy
Volume10
Issue number4
Publication statusPublished - Oct 2003
Peer-reviewedYes

External IDs

Scopus 0348048493

Keywords

Sustainable Development Goals

Keywords

  • advanced glycation end products, uremia, GLUCOSE DEGRADATION PRODUCTS, PERITONEAL-DIALYSIS FLUID, REACTIVE CARBONYL-COMPOUNDS, INCREASED OXIDATIVE STRESS, ENDOTHELIAL GROWTH-FACTOR, MAILLARD REACTION-PRODUCT, IMIDAZOLIUM CROSS-LINKS, N-ALPHA-HIPPURYLLYSINE, STAGE RENAL-FAILURE, IN-VITRO